XRBWEERUFFCMDN-AZMWARKLSA-N
C16H14N8O7S3 — CID 131712399
Data last refreshed: (MolForge compound catalog, from PubChem)
About XRBWEERUFFCMDN-AZMWARKLSA-N
XRBWEERUFFCMDN-AZMWARKLSA-N (PubChem CID 131712399) has the molecular formula C16H14N8O7S3 and a molecular weight of 526.54 g/mol. Its IUPAC name is (6R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-oxoacetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.
Molecular Properties
| Compound Name | XRBWEERUFFCMDN-AZMWARKLSA-N |
|---|---|
| PubChem CID | 131712399 |
| Molecular Formula | C16H14N8O7S3 |
| Molecular Weight | 526.54 g/mol |
| Exact Mass | 526.01 |
| IUPAC Name | (6R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-oxoacetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| SMILES | Nc1nc(C(=O)C(=O)NC2C(=O)N3C(C(=O)O)=C(CSc4nnnn4CC(=O)O)CS[C@H]23)cs1 |
| InChI | InChI=1S/C16H14N8O7S3/c17-15-18-6(4-33-15)10(27)11(28)19-8-12(29)24-9(14(30)31)5(2-32-13(8)24)3-34-16-20-21-22-23(16)1-7(25)26/h4,8,13H,1-3H2,(H2,17,18)(H,19,28)(H,25,26)(H,30,31)/t8?,13-/m1/s1 |
| InChIKey | XRBWEERUFFCMDN-AZMWARKLSA-N |
| XLogP | -1.49 |
| TPSA | 223.59 Ų |
| H-Bond Donors | 4 |
| H-Bond Acceptors | 14 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 526.54 |
| LogP ≤ 5 | -1.49 |
| H-Bond Donors ≤ 5 | 4 |
| H-Bond Acceptors ≤ 10 | 14 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'diketo_group', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 131712399 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.